Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

American Journal of Clinical Dermatology

Volumn 16, Issue 4, 2015, Pages 323-330

  Garnock Jones, Karly P ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; PLACEBO; SECUKINUMAB; DERMATOLOGICAL AGENT; IL17A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAIL PSORIASIS; PHARMACODYNAMICS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; SHORT COURSE THERAPY; SYSTEMIC THERAPY; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; ANTAGONISTS AND INHIBITORS; PATHOLOGY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; INTERLEUKIN-17; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84938824470     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-015-0143-7     Document Type: Article

References (39)

1. Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther. 2014;4(1):1–9.
2. Adami S, Cavani A, Rossi F, et al. The role of interleukin-17A in psoriatic disease. BioDrugs. 2014;28(6):487–97.
3. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1–70.
4. Novartis Europharm Limited. Cosentyx™ (secukinumab subcutaneous injection): EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 18 Jun 2015.
5. Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50.
6. Novartis Pharmaceuticals Corporation. Cosentyx™ (secukinumab subcutaneous injection): US prescribing information. 2015. http://www.pharma.us.novartis.com. Accessed 18 Jun 2015.
7. Novartis Pharmaceuticals Corporation. Advisory Committee briefing materials: secukinumab. 2014. www.fda.gov. Accessed 18 Jun 2015.
8. Kolbinger F, Bruin G, Valentin MA, et al. Secukinumab treatment rapidly leads to positive proteomic and transcriptional changes in psoriatic skin [abstract no. P1656]. In: 23rd congress of the European Academy of Dermatology and Venereology. 2014.
9. Krueger J, Wharton K, Fuentes-Duculan J, et al. Secukinumab reverses disease-defining psoriasis histopathology while retaining full T-cell activation potential [abstract no. P43]. Br J Dermatol. 2014;171:e140.
10. Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015. doi:10.1111/exd.12710.
11. Bruin G, Dragatin C, Aigner B, et al. Secukinumab, a novel anti-IL-17A antibody, can be quantified in skin after a single dose by dermal open flow microperfusion (dOFM) [abstract]. J Dtsch Dermatol Ges. 2014;12(Suppl 1):15.
12. Gottlieb A, Sigurgeirsson B, Blauvelt A, et al. Secukinumab reduces hsCRP levels in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a sub-analysis from the phase 3 ERASURE study [abstract no. AB0738]. Ann Rheum Dis. 2014;73(Suppl 2):1047.
13. Strober B, Guettner A, Sigurgeirrson B, et al. Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: result of a regimen-finding study [abstract no. P6395]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.
14. Mrowietz U, Qureshi A, Escrig C. Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled, phase II study [abstract no. P6871]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.
15. Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19(10):1597–602.
16. US FDA. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting background package for BLA 125504 Cosentyx (secukinumab). 2014. http://www.fda.gov. Accessed 18 Jun 2015.
17. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11.
18. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–21.
19. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.
20. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014;172(2):484–93.
21. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2014;29(6):1082–90.
22. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015. doi:10.1016/j.jaad.2015.05.013.
23. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab efficacy and safety in subjects with moderate to severe palmoplantar psoriasis in a phase 3b study (GESTURE) [abstract no. FC24-07]. In: 23rd World Congress of Dermatology. 2015.
24. Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with nail psoriasis: 16 week results from the TRANSFIGURE study [abstract]. In: 23rd World Congress of Dermatology. 2015.
25. Papp K, Karpov A, Papavassilis C, et al. Secukinumab efficacy in relationship with response to previous biologic psoriasis therapy: a subanalysis from the ERASURE Study [abstract no. P8011]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB186.
26. Blauvelt A, Gottlieb A, Sigurgeirsson B, et al. Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study [abstract no. P8033]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB2.
27. Philipp S, Papavassilis C, Notter M, et al. Secukinumab effect on functional ability in subjects with moderate to severe plaque psoriasis and psoriatic arthritis: a subanalysis from the FIXTURE study [abstract no. P8098]. J Am Acad Dermatol. 2014;70:AB185.
28. Blauvelt A, Szepietowski J, Sigurgeirrson B, et al. Secukinumab treatment maintains efficacy in moderate to severe plaque psoriasis through second year of treatment: a randomized extension of the ERASURE and FIXTURE studies [abstract]. In: 73rd annual meeting of the American Academy of Dermatology. 2015.
29. Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36 e1.
30. Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015. doi:10.1111/bjd.13814.
31. Tsai T, Blauvelt A, Karpov A, et al. Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis [abstract no. 193]. J Invest Dermatol. 2014;134:S33.
32. Griffiths C, Guettner A, Prinz J, et al. Secukinumab safety in subjects with moderate to severe plaque psoriasis: a pooled analysis of neutropenia from 10 clinical studies [abstract no. P8266]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB188.
33. Van De Kerkhof P, Strober B, Karpov A, et al. Evaluation of malignancy risk with secukinumab treatment in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis up to 52 weeks [abstract no. 194]. J Invest Dermatol. 2014;134:S33.
34. Craig L, Nehal M, Mark L, et al. Incidence of major adverse cardiovascular events with secukinumab: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis [abstract no. T.106]. In: Federation of Clinical Immunology Societies Annual Meeting. 2014.
35. Ward N, Guettner A, Sands B, et al. Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: a pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn’s disease [abstract no. P8233]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB188.
36. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a novel Anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays [abstract no. 1320]. In: 73rd annual meeting of the American Academy of Dermatology. 2015.
37. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.
38. Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76(6):634–44.
39. Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–38.